Abstract: The invention provides a method of determining a prognosis for survival for a patient with a prostate neoplastic condition. The method consists of (a) measuring the level of XIAP in a neoplastic prostate cell-containing sample from the patient, and (b) comparing the level of XIAP in the sample to a reference level of XIAP, where an increased level of XIAP in the sample correlates with increased survival of the patient.
Abstract: Disclosed herein are compositions and methods relating to a peptide that inhibits Nod-like Receptors. Further provided are compositions and methods for treating or preventing inflammation, including diseases associated with inflammation such as inflammatory bowel disease, Crohn's disease, ulcerative colitis, arthritis, psoriasis, Alzheimer's disease, cardiovascular disease, diabetes, and sepsis.
Type:
Application
Filed:
July 16, 2009
Publication date:
April 15, 2010
Applicant:
Burnham Institute for Medical Research
Inventors:
John C. Reed, Benjamin Faustin, Arnold Satterthwait
Abstract: The invention provides a conjugate that includes a therapeutic moiety linked to a peptide or peptidomimetic that selectively homes to vasculature of premalignant pancreas. The peptide or peptidomimetic contains at least 5 contiguous amino acids of an amino acid sequence selected from CRSRKG (SEQ ID NO:9) and CEYQLDVE (SEQ ID NO:34), or a conservative variant or peptidomimetic thereof. The invention additionally provides a conjugate containing a therapeutic moiety linked to a peptide or peptidomimetic that selectively homes to pancreatic tumor cells and pancreatic tumor vasculature, the peptide or peptidomimetic comprising at least 5 contiguous amino acids of an amino acid sequence selected from CKAAKNK (SEQ ID NO:15), CKGAKAR (SEQ ID NO:19), and VGVGEWSV (SEQ ID NO:35), or a conservative variant or peptidomimetic thereof.
Type:
Application
Filed:
September 14, 2009
Publication date:
March 25, 2010
Applicants:
BURNHAM INSTITUTE FOR MEDICAL RESEARCH, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
Douglas Hanahan, Erkki Ruoslahti, Johanna A. Joyce, Pirjo Laakkonen
Abstract: The present invention provides a conjugate containing a moiety linked to a homing molecule that selectively homes to tumor lymphatic vasculature. The invention also provides a method of directing a moiety to tumor lymphatic vasculature in a subject by administering to the subject a conjugate containing a moiety linked to a homing molecule that selectively homes to tumor lymphatic vasculature.
Type:
Grant
Filed:
February 27, 2007
Date of Patent:
March 2, 2010
Assignee:
Burnham Institute for Medical Research
Inventors:
Pirjo Laakkonen, Kimmo Porkka, Jason A. Hoffman, Erkki Ruoslahti
Abstract: The invention provides isolated nucleic acid molecules encoding PAAD-domain containing polypeptides and functional fragments thereof, including fragments containing PAAD domains, NACHT domains and ARED domains, encoded polypeptides, and antibodies. Also provided are methods of identifying polypeptides and agents that associate with a PAAD-domain containing polypeptide or fragment thereof, or that alter an association of a PAAD domain-containing polypeptides. Further provided are methods of identifying agents that modulate PAAD domain-mediated inhibition of NFKB activity, or modulate an activity of a NACHT domain of a PAAD domain-containing polypeptide. Also provided are methods of modulating NFKB transcriptional activity in a cell, and methods of altering expression of a PAAD domain-containing polypeptide in a cell.
Abstract: We have developed a reduced Drosophila heart preparation in which dissection of the fly heart removes nervous system input and reveals its inherent myogenic activity, which can be preserved for several hours. High speed image capture combined with computer-based analytical packages allows us to generate the equivalent of M-mode traces obtained from ultrasounds of human hearts.
Type:
Application
Filed:
August 20, 2009
Publication date:
February 25, 2010
Applicants:
BURNHAM INSTITUTE FOR MEDICAL RESEARCH, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Abstract: In accordance with the present invention, there are provided novel TRAF-Protein-Binding-Domain polypeptides (TPBDs). The invention also provides nucleic acid molecules encoding TPBDs, vectors containing these nucleic acid molecules and host cells containing the vectors. The invention also provides antibodies that can specifically bind to invention TPBDs. Such TPBDs and/or anti-TPBD antibodies are useful for discovery of drugs that suppress autoimmunity, inflammation, allergy, allograph rejection, sepsis, and other diseases.
Abstract: The present invention provides a method of directing a moiety to breast vasculature in a subject by administering to the subject a conjugate which contains a moiety linked to a homing molecule that selectively homes to breast vasculature, whereby the moiety is directed to breast vasculature. In one embodiment, the homing molecule is a peptide containing the amino acid sequence PGPEGAG (SEQ ID NO: 1), or a peptidomimetic thereof.
Abstract: The present disclosure provides compounds having the general structure A or pharmaceutically acceptable salts thereof: R—X??(A) wherein R is an alkyl or aryl moiety comprising heterocyclic structures; and X is a metal-chelatin group selected from: This disclosure further provides a focused library of compounds for use in the discovery and design of metallo-enzyme inhibitors. This fragment-based approach provides an assembly of a library of low molecular weight compounds (MW<300 Da) containing a variety of potential metal-chelating groups. The identification of the inhibitory scaffolds among these compounds provides the initial hit fragments that may be optimized for affinity against a particular target using common medicinal chemistry, structure-based or NMR-based approaches.
Type:
Application
Filed:
August 14, 2009
Publication date:
February 18, 2010
Applicants:
BURNHAM INSTITUTE FOR MEDICAL RESEARCH, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Abstract: This disclosure generally relates to components and methods of using a high throughput screening (HTS) systems for intracellular proteases, using Caspases as a prototype. Genetic systems are disclosed for monitoring exogenous caspase activation pathways in the yeast, Saccharomyces cerevisiae. The yeast-based cellular systems permit facile expression of proteases (e.g., caspase) and protease-activating proteins in combinations that reconstitute entire mammalian pathways in these simple eukaryotes. Among the assay methods integrated into the yeast system are cleavable reporter gene activators, in which protease-mediated cleavage activates a transcription factor. Exemplary systems rely, singly or in concert, on exogenous recombinant caspases and exogenous upstream activators of caspases to cleave a chimeric protein giving rise to a transcription factor which induces the expression of the LacZ and LEU2 genes.
Type:
Application
Filed:
July 16, 2009
Publication date:
February 4, 2010
Applicant:
Burnham Institute for Medical Research
Inventors:
John C. Reed, Hideki Hayashi, Michael Cuddy
Abstract: Disclosed are modulators, i.e., activators and inhibitors, of Intestinal Alkaline Phosphatase (IAP). Also disclosed are methods for treating bacterial infections of the intestinal tract and methods for maintaining the health of the intestinal tract using IAP activators. Further disclosed are methods to assist in weight gain of emaciated patients and those having reduced or negligible fat absorption using IAP inhibitors.
Type:
Application
Filed:
May 19, 2009
Publication date:
January 21, 2010
Applicant:
Burnham Institute for Medical Research
Inventors:
Jose Luis Millan, Sonoko Narisawa, Eduard Sergienko
Abstract: The invention provides Bcl-G polypeptides and encoding nucleic acids. Bcl-G polypeptides include Bcl-GL and Bcl-GS. The invention also provides mouse Bcl-G. The invention also provides vectors containing Bcl-G nucleic acids, host cells containing such vectors, Bcl-G anti-sense nucleic acids and related compositions. The invention additionally provides Bcl-G oligonucleotides that can be used to hybridize to or amplify a Bcl-G nucleic acid. Anti-Bcl-G specific antibodies are also provided. Further provided are kits containing Bcl-G nucleic acids or Bcl-G specific antibodies. Such kits and reagents can be used to diagnose cancer, monitor response to therapy, or predict the prognosis of a cancer patient. The invention additionally provides methods of modulating apoptosis using Bcl-G polypeptides, encoding nucleic acids, or compounds that modulate the activity or expression of Bcl-G polypeptides. The methods for modulating apoptosis can be used to treat diseases such as cancer.
Abstract: The invention provides caspase recruitment domain (CARD)-containing polypeptides, CARD, NB-ARC, ANGIO-R, LRR and SAM domains therefrom, as well as encoding nucleic acid molecules and specific antibodies. The invention also provides related screening, diagnostic and therapeutic methods.
Type:
Grant
Filed:
March 26, 2007
Date of Patent:
December 1, 2009
Assignee:
Burnham Institute for Medical Research
Inventors:
John C. Reed, Frederick F. Pio, Adam Godzik, Christian Stehlik, Jason S. Damiano, Sug Hyung Lee, Vasco A. Oliveira, Hideki Hayashi, Kryzysztof Pawlowski
Abstract: The present invention provides a family of BAG-1 related proteins from humans (BAG-1L, BAG-1, BAG-2, BAG-3, BAG-4 and BAG-5), the invertebrate C. elegans (BAG-1, BAG-2) and the fission yeast S. pombe (BAG-1A, BAG-1B) and the nucleic acid molecules that encode them.
Abstract: Provided herein are compositions and methods of detecting Bcl-B expression in cancer cells to prognose, monitor, or select therapies for cancers such as breast cancer, prostate cancer, lung cancer, or gastric cancer.
Abstract: The invention provides isolated MMP-2, MMP-9 and MT1-MMP selective substrate polypeptides or functional peptidomimetics. The selective substrate polypeptides contain the following sequences: MMP-2 selective substrate polypeptides contain SEQ ID NOS:1-27, MMP-9 selective substrate polypeptides contain SEQ ID NOS:28-35, and MT1-MMP selective substrate polypeptide contain SEQ ID NOS:36-40. In addition, the invention provides a method of preferentially directing a moiety to a site of MMP-2 activity by administering to a subject an effective amount of an isolated MMP-2 selective substrate polypeptide containing SEQ ID NOS:45-47 linked to a moiety.
Type:
Application
Filed:
October 15, 2008
Publication date:
October 8, 2009
Applicant:
Burnham Institute for Medical Research
Inventors:
Jeffrey W. Smith, Emily I. Chen, Steven J. Kridel
Abstract: A method to identify selective inhibitors of antigen receptor-mediated NF-?B activation is provided, as well as compositions having one or more of those inhibitors and methods of using those inhibitors.
Type:
Application
Filed:
March 26, 2009
Publication date:
October 1, 2009
Applicants:
The Burnham Institute for Medical Research, The Human Biomolecular Research Institute
Inventors:
John C. REED, Ranxin SHI, John R. Cashman, Karl J. OKOLOTOWICZ, Daniel RE